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Effects of transforming growth factor beta (TGF-fJ) on prolif-
erative responses to basic fibroblast growth factor (bFG8) 
were studied in human diploid fibroblasts cell strains derived 
from three different sources: adult skin, scleroderma, and 
newborn foreskin. All three types of cell strains were simi-
larly responsive to TGF-fJ, wh~reas adult skin fibr~blasts 
were significantly more responslve to bFGF. IncubatlOn C)f 
cells with TGF-fJ prior to bFGF addition substantially in.-
creased responsiveness of adult skin fibroblasts to this latter 
cytokine, slightly increased that of scleroderma fibroblasts, 
and decreased that of foreskin fibroblasts. Modulation C)f 
bFGF receptors by TGF-fJ correlated positively with these 
mitogenic effects. Adult skin fibroblasts showed increases C)f 
B asic fibroblast growth factor (bFGF) belongs to a faIU-ily of proteins involved in the regulation of growth aQ.d development of cells of mesodermal and neuroectoder-mal origin [1,2]. Biologic effects ofbFGF are medlat~d through high-affinity (Kd = 2 - 20 X 10- 11 M) recelJ-
tors inciudingJlg and bek gene products that have intrinsic tyrositle 
kinase activity [3-6]. Depending on cell type, 3,000 to 80,000 of 
these high-affinity sites are present on the cell surface [7]. In addi-
tion, bFGF binds with low affinity (Kd = 2 X 10-9 M) to hepar~[l 
sulphate proteoglycans (HSPG) [8]. Although these low-affinity 
receptors are abundant on the cell surface, HSPG are also compo-
nents of extracellular matrix [9]. Early studies indicated that tbe 
low-affinity receptors could provide protection for ' FGF again.st 
proteolytic degradation, thus serving as an FGF reservoir [8 -11.]. 
Recent studies provide evidence that low-affinity receptors also pl<l)' 
a role in receptor-mediated biologic effects. For example, mutan.ts 
of CHO cells lacking surface HSPG were unable to bind bFGF to 
high-affinity receIJtors unless .heparin or ?e~ara~ sulphate was pru-
vided in the medIUm [12]. Similarly, eliminatIOn of heparan Sll.l-
phate by heparitinase or by chlorate treatment resulted in lo:ver 
binding to both types of cell-surface receptors and reduced mltu-
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both high- and low-affinity receptors and scleroderma fibro-
blasts showed small increases of high-affinity receptors only, 
whereas foreskin fibroblasts showed no changes. Heparitin-
ase treatment of adult skin fibroblasts during TGF-fJ pre-in-
cubation resulted in reduced bFGF binding to low-affinity 
receptors and reduced mitogenic response to bFGF, suggest-
ing that the TGF-fJ - stimulated increase of low-affinity re-
ceptors in these cells contributes to the observed enhanced 
mitogenic effects of bFGF. Abnormal responses of sclero-
derma fibroblasts to TGF-fJ/bFGF stimulation, particularly 
failure to synthesize low-affinity receptors in response to 
TGF-fJ, adds a new characteristic to the fibrotic phenotype of 
scleroderma fibroblasts. ] Invest Dermatol 99:201 - 205, 1992 
genic responses to bFGF of Swiss 3T3 cells or induced terminal 
differentiation of MM14 skeletal muscle cells [13] . These studies 
indicate that low-affinity receptors may be directly involved in 
bFGF cell signaling. 
Scleroderma [systemic sclerosis (SSc)] is a complex connective 
tissue disease of unknown etiology, in which development of fibro-
sis is prominent in the skin and various organs. Scleroderma fibro-
blasts express a phenotype different from that of normal skin fibro-
blasts . Characteristics of this phenotype include enhanced mRNA 
expression of several extracellular matrix genes (collagens I, III, VI, 
fibronectin, proteoglycan) [14] and abnormalities of cell growth 
that include persistent c-myc mRNA expression [15] . Our recent 
studies also indicate that scleroderma fibroblasts exhibit distinctive 
upregulation ofPDGF a receptors after TGF-fi stimulation as com-
pared to adult skin and foreskin fibroblasts [16,17]. Effects ofTGF-fi 
on platelet-derived growth factor (PDGF) a receptor expression 
correlated positively with mitogenic responses to PDGF-AA. In-
creased responses and upregulation of a receptor subunit expression 
were observed in scleroderma fibroblasts; variable, but usually un-
changed responses were observed in adult skin fibroblasts , and de-
creased a subunit expression and mitogenic responses were ob-
served in newborn foreskin fibrobl as ts. Different effects of TG F-fi 
on growth regulation in these closely related human fibroblast 
strains may be relevant to the process of wound healing and fibrosis. 
bFGF is one of the growth factors present in wounds as well as in 
fibrotic lesions, including scleroderma [18,19] . We therefore exam-
ined effects ofTGF-fi on mitogenic responses to bFGF in adult skin, 
scleroderma skin, and newborn foreskin fibroblasts. 
MATERIALS AND METHODS 
Materials TGF-fi1 and recombinant human bFGF were pur-
chased from R&D Systems, Inc. (Minneapolis, MN). Heparinase I 
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(EC 4.2.2.7) and heparitinase I (EC 4.2.2.8) were purchased from 
Sigma (St. Louis, MO). 
Cells Fibroblas ts were propagated from skin biopsies from af-
fected areas of patients with diffuse cutaneous systemic sclerosis 
(SSc) with less than two years of skin thickening. Within several 
days control fibroblasts were obtained by biopsy of healthy donors 
matched with each SSc patient for age, race, sex, and biopsy site and 
processed in parallel. N ewborn foreskin fibroblasts were obtained 
from the delivery suites of affiliated hospitals. All biopsies were 
obtained after informed consent and institutional approval. Primary 
explant cultures were established in 25-cm2 culture flasks (Costar, 
Cambridge, MA) in Dulbecco's modified Eagle's medium (DMEM) 
(Gibco, Grand Island, NY) supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, 50 ,ug/ml gentamicin sulfate (Quality 
Biological, Inc., Gaithersberg, MD). Amphotericin (5 ,ug/ml) 
(Gibco, Grand Island, NY) was included for the first week only. 
Monolayer cultures were maintained at 37"C in 5% CO2 in air. 
Fibroblasts between the second and fourth subpassages were used for 
experiments. 
DNA Synthesis Growth-factor responses were measured by 
[3H]thymidine incorporation. Cells (2 X 104/well) were plated in 
24-well trays in DMEM medium with 10% FCS and grown to near 
confluence; two wells from each plate were used for cell number 
determination (mean ± SD = 3 ± 0.7 X 104 for SSc cells, 3.2 ± 
0.5 X 104 for NS cells, and 3.4 ± 0.9 X 104 for FS fibrobl asts), fol-
lowed by synchronization with serum-free DMEM containing 
0.1 % BSA (SFM). Control cultures received no growth factors and 
no serum after synchronization. bFGF (1 ng/ml) and TGF-p (1 
ng/ml) were added to cells in SFM. Cells were labeled with 
[3H]thymidine (specific activity 3.22 Bq/mmol, final concentration 
1 ,uCi/ml; NEN, Boston, MA), for 2 h, washed three times with 
cold PBS, and three times with 5% trichloracetic acid. Five-
hundred microliters of 0.1 % NaOH/O.l % SDS was added and the 
radioactivity of 250,u1 aliquots was measured in 5 ml of PCS II 
(Amersham Corporation, Arlington H eights, IL) using liquid scin-
tillation spectrometry (Packard, Sterling, V A). All experiments 
were done in triplicate. 
1251 bFGF Binding Assay 125I-labeled bFGF was purchased from 
Biomedical T echnologies, Inc., Stoughton, MA (specific activity 
195 ,uCi/,ug). Cells were plated at 2 X 104 cells/well and incubated 
overnight in 10% FCS. Binding was determined with 1251-labeled 
bFGF using the procedure of Moscatelli [8]. Cells were incubated 
with various concentration of 1251-labeled bFGF (0.25 -1000 ng/ 
ml) in DMEM containing 0.15% gelatin and 25 mM HEPES at pH 
7.5 for 2 h at 4 0 C. After incubation, medium was removed, and 
cells were washed with cold PBS; medium and washes were com-
bined to determine the amount of free ligand. Cells were washed 
twice with 2 M N aCI in 20 mM HEPES at pH 7.5 to determine 
low-affinity binding and then with 2 M N aCI in 20 mM sodium 
acetate at pH 4.0 to determine high-affinity binding. Nonspecific 
binding was determined by the addition of 200-times excess (maxi-
mum 200 nM) of unlabeled bFGF. To ensure that equal number of 
cells were used for assays, duplicate wells were used for cell number 
determination. (Mean cells per well = 1.56 ± 0.62 X 104 ) . 
Modulation ofbFGF Receptors by Heparitinase Confluent, 
synchronized fibroblast cultures in 24-well plates were treated with 
1 ng/ml of TGF-p in serum-free medium for 8 h . During the last 
3 h of incubation with TGF-p, heparitinase I (0.5 U /ml) or heparin-
ase I (3 U / ml) was added to some cells. After incubation, cells were 
washed twice with serum-free medium and used for either the mi-
togenic assay or the 1251 bFGF binding assay (see above). 
RESULTS 
Effects ofTGF-p on Mitogenic Responses to bFGF Are Cell-
Strain Dependent Our previous data indicated that responses of 
human fibroblasts of different origins (adult skin, scleroderma skin, 
and newborn foreskin) to combinations of TGF-p and PDGF-AA 
were different for the three skin types [16,17]. To examine whether 
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Figure 1. Effect ofTGF-/1pre-incubation on mitogenic responses to bFGF 
in adult skin fibroblasts (NS), scleroderma fibrobl asts (SSe), and newborn 
foreskin fibroblasts (FS). Confluent cells made quiescent by serum depriva-
tion were stimulated with TGF-/1 (1 ng/ml) alone, or bFGF (1 ng/ml) alone. 
or pretreated with TGF-/1 for 8 h and then stimulated with bFGF. Growth 
factors were added in serum-free medium supplemented with 0.1 % BSA. 
Cells were labeled for 2 h with [3HJthymidine added 30 h after growth-fac-
tor addition. Values represent mean ± SD from six adult skin. six sclero-
derma. and three foreskin cell lines; each experiment was performed in 
triplicate wells. [3HJthymidine incorporation (cpm) in control wells. which 
received no growth factors, was set at 100%; values for growth-factor-
stimulated cells represent increases over control (mean ± SD of cpm in 
control wells = 518 ± 88 for NS fibroblasts, 525 ± 69 for SSc fibroblasts . 
and 519 ± 44 for FS fibroblasts). . 
the effect of TGF-p on the proliferative responses to bFGF also 
diffe rs in these cell strains, we used an experimental design similar 
to one developed in PDGF-AA studies using serum-free conditions. 
To maximize the effects of TGF-p, bFGF and TGF-p were not 
added together; instead cells were pre-incubated with 1 ng/ml of 
TGF-p for 8 h before bFGF addition (pre-treatment for 4,6, 12, or 
16 h resulted in smaller effects. data not shown). In a typical experi-
ment cells were grown to confluence, deprived of serum for 24 h, 
and stimulated with various combinations of growth factors added 
in serum-free medium. One group of cells was pretreated with 
TGF-P (lng/ml) for 8 h then stimulated with bFGF (1 ng/ml) for 
30 h. Another group was treated with TGF-p for 8 h. and the me-
dium was changed to DMEM/O.l % BSA (serum-free medium) for 
30 h. A third group, after 8 h incubation in serum-free medium. 
received bFGF for 30 hours. The control group was maintained in 
serum-free medium. After stimulation with growth factors. 
[3H]thymidine was added to all cells for 2 h and incorporation of 
[3H]thymidine was determined. As shown in Fig 1. all three cell 
strains responded similarly to TGF-p; however, adult skin fibro-
blasts were more responsive to bFGF. Increases in thymidine incor-
poration caused by exposure to bFGF were significantly greater 
(503 ± 77%) than for scleroderma fibroblasts (167 ± 21 %) (p < 
0.05) . Although pre-incubation of cells with TGF-p synergistically 
enhanced DNA synthesis by adult skin fibroblasts in response to 
bFGF (p < 0.002). in scleroderma fibroblasts only statistically insig-
nificant increases were noted. In contrast. the mitogenic responses 
to bFG F were reduced by TG F-P pretreatment of all foreskin fibro-
blasts. 
TGF-p Modulates bFGF Receptors To ask whether effects of 
TGF-P on mitogenicity of bFGF correlate positively with changes 
in bFGF receptors, we tested specific binding of 1251-labeled bFGF 
before and after TGF-p treatment to calculate binding-site affinity 
and prevalence by Scatchard analysis. Figure 2 shows a typical analy-
sis in adult skin fibroblasts and T able I summarizes results obtained 
from three cell strains. Basal levels of high-affinity receptors were 
similar in scleroderma and normal fibroblasts and slightly increased 
after TGF-p treatment in both cell strains . However, levels oflow-
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Figure 2. Effect ofTG F-P on bFGF receptors. Cells were plated and grown 
overnight in 10% FCS in 24-well plates, followed by 24-h incubation in 
serum-free medium. Cells were then incubated with 1 ng/ml ofTGF-p for 
8 h. Control cells were incubated in serum-free medium during this time. 
Cells were washed and the 125I-Iabeled bFGF binding assay was performed as 
described in Materials and Methods. A, Scatchard analysis of high-affinity 
receptors; B, low-affinity receptors. (e) cells pretreated with TGF-p; (0) 
control cells. 
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Table I . Effect of TGF-fi on FGF Receptor Number 
High Affinity Low Affinity 
Basal Basal 
Expression Expression Expression Expression 
X 10' After TGF-p X 105 After TGF-p 
NS' 2.9 ± 0.8 5.5 ± 0.7 2.5 ± 0.7 7.5 ± 1.8 
SSe 4.7 ± 1.3 5.9 ± 2.0 1.3 ± 0.2 1.1 ± 0.1 
FS 0.86 ± 0.28 0.78 ± 0.17 8.2 ± 1.2 6.9 ± 1.3 
, Values represent mean ± SD of receptor number percell from four adult skin (NS), 
four scleroderma (SSe), and three newborn foreskin (FS) cell lines. 
affinity receptors were significantly higher in normal fibroblasts 
(2.5 ± 0.7 X 105) than in scleroderma fibroblasts (1.3 ± 0.2 X 105) 
(p < 0.05). Low-affinity receptor number was further increased by 
TGF-fi only in normal fibroblasts (7.5 ± 1.8 X 105) (p < 0.04), 
whereas scleroderma fibroblasts showed no increase. Foreskin fibro-
blasts exhibited different levels of both high- and low-affinity re-
ceptors, which remained unchanged after TGF-fi treatment. The 
dissociation constants for bFGF binding by all fibroblasts straip.s 
were 54 ± 2.3 X 10-11 M (high affinity) or 2.21 ± 1.04 X 10-9 M 
(low affinity). 
Low-Affinity Receptors Are Involved in Mitogenic Res-
ponses Enhancement by TGF-fi of mitogenic response to bFGF 
was significantly greater in adult skin fibroblasts compared to sclero-
derma fibroblasts and correlated positively with increases in both 
types of receptors; in scleroderma fibroblasts, only small increases in 
high-affinity receptors were observed. To further investigate 
whether changes in low-affinity receptors in adult skin fibroblasts 
contribute to mitogenic effects ofbFGF, heparitinase was included 
during TGF-fi pre-incubation. Subsequently binding of 125I-labeled 
bFGF showed that heparitinase treatment decreased binding to 
low-affinity sites by 60% (p < 0.05) (Fig 3), whereas binding to 
high-affinity sites remained unchanged. The enzymatic treatment 
had no effect on cell viability. In parallel experiments effects of 
heparitinase treatment on mitogenic responses to bFGF were 
examined. As shown in Table II, without TGF-fi pre-incubation, 
heparitinase only slightly decreased mitogenic responses to bFGF. 
However, heparitinase treatment significantly reduced TGF-fi-
stimulated increase of mitogenic response in adult skin fibroblasts 
(p < 0.01). Similar results were obtained using heparinase treat-
ment (data not shown). 
DISCUSSION 
In this study we investigated mitogenic responses to bFGF and 
TGF-fi in strains of human diploid fibroblasts from three different 
sources. Although all three types of cell strains responded similarly 
to TGF-fi, significant differences between cell strains were found in 
responses to bFGF alone or in combination with TGF-fi. Human 
adult fibroblasts were more responsive to bFGF than either sclero-
derma or newborn foreskin fibroblasts. These data corroborate an 
earlier finding by Takehara et al [20]' who also observed reduced 
responses of scleroderma fibroblasts to FGF. The mechanism of 
decreased mitogenic responsiveness of scleroderma fibroblasts to 
bFGF is unknown. There is no correlation with high-affinity recep-
tor levels as these are slightly higher in scleroderma fibroblasts. 
However, reduced numbers of low-affinity receptors in sclero-
derma fibroblasts may contribute to this effect. Alternatively, post-
receptor signaling may be altered in scleroderma fibroblasts result-
ing in decreased mitogenic responses to bFGF. Pretreatment of cells 
with TGF-fi modulated responses to bFGF. Significant increases 
were observed in adult skin .fibroblasts; small increases in sclero-
derma fibroblasts and decreased responses were characteristic of fore-
skin fibroblasts. Effects of TGF-fi pretreatment on bFGF receptor 
expression correlated with these proliferative responses. In adult 
skin fibroblasts, both high- and low-affinity receptors were in-
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Figure 3. Effect ofheparitinase treatment on bFGF receptor binding. Con-
fluent fibroblasts grown in 24-well plates were made quiescent by serum 
deprivation and incubated with 1 ng/ml ofTGF-/l in SFM for 8 h. During 
the last 3 h of incubation with TGF-/l, half of the cells received heparitinase 
(0.5 U/ml). Binding assay with 12s1 bFGF was then performed as described 
(see Fig 2 and Materials and Methods). Figure represents mean ± SD from four 
cell lines. 
creased; in scleroderma, only slight increases of high-affinity recep-
tors were noted; whereas in foreskin fibroblasts bFGF receptors 
were not affected .by TGF-p exposure. We further investigated 
whether the TGF-fJ-stimulated increase of low-affinity receptor 
number in adult skin fibroblasts contributed to the observed en-
hanced mitogenic effects ofbFGF. Heparitinase treatment reduced 
binding to low-affinity receptors by 60%, whereas binding to high-
affinity receptors remained unchanged. In parallel experiments he-
paritinase treatment also decreased mitogenic response to bFGF. 
These data suggest that heparan-sulphate binding ofbFGF directly 
contributes to its mitogenic effects in adult skin fibroblasts. Related 
studies by Rapraeger et al [13], using either sodium chlorate or 
heparitinase digestion, reported inhibition ofbFGF binding to both 
high-affinity and low-affinity receptors. Conditions of heparitinase 
digestion used in our study resulted only in partial decrease of low-
affinity receptors. Both a different experimental design (heparitin-
ase is known to be unstable in tissue culture medium) and different 
cells (murine immortal cell line) could account for these differences. 
Unlike adult skin fibroblasts, scleroderma fibroblasts showed no 
increase of low-affinity receptors before or after TGF-p treatment. 
This is surprising, because scleroderma fibroblasts constitutively 
produce excess glycosaminoglycans and, in addition, TGF-p in-
duces higher total glycosaminoglycan (GAG) synthesis in sclero-
derma than in adult skin fibroblasts in both the extracellular and 
cellular compartments [21,22]. The mitogenic differences could be 
explained by qualitative differences in TGF-fJ-induced GAG be-
tween scleroderma and normal fibroblasts. The characteristics of 
cell-surface HSPG that interact with bFGF are largely ·unknown. 
Recently, one possible candidate, syndecan, has been identified 
[23,24] . Whether scleroderma fibroblasts failed to synthesize syn-
decan or another presently uncharacterized HSPG remains to be 
determined. 
The present findings are yet another manifestation of growth and 
matrix abnormalities of scleroderma fibroblasts. The fibrotic pro-
cess in scleroderma can be viewed as unregulated wound healing. 
Similarities in expression of smooth muscle cells markers (0' actin, 
des min, and vim en tin) between scleroderma fibroblasts and the fi-
broblasts present in early wounds have been noted [25 - 27]. Because 
fibroblasts derived from different stages of wounds differ phenotypi-
cally in their responses to growth factors [28], it would be of great 
interest to systematically compare scleroderma and wound fibro-
blasts. Significantly different responses of foreskin fibroblasts to a 
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Table II. Effect of Heparitinase Treatment on Proliferative 
Responses· _ 
NS SSc FS 
--------------------------------------------------
N/ A 99.8 ± 1.6 100.4 ± 2.5 98 ± 7.6 
TGF/l 101.8 ± 2.4 100.8 ± 3.4 105 ± 5.0 
FGF 85 ± 20 94.8 ± 2.1 80 ± 26.4 
TGF/l + FGF 49 ± 6 89.2 ± 3.6 105 ± 5.0 
-----------------------------------------------------
• Values represent mean ± SD from 5 adult skin (NS) , five scleroderma skin (S;Uj' 
and three foreskin (FS) cell strains, each experiment performed in triplicate wells. [ 
thymidine incorporation (cpm) in control cells, which did not receive heparitinase, was 
set at 100%; values from heparitinase treated cells represent percent of control. 
variety of growth factors preclude them from serving as model ceIl 
lines to study human fibrosis or as adequate controls for either sclero-
derma or wound fibroblasts. F 
It should be noted that the TGF-fJ-induced effects on b~G 
mitogenesis reported herein and TGF-fJ effects on PDGF, especlaIly 
the A ligand/a receptor arm of that system, reported by us else-
where are distinct [16,17]. In the present study, healthy adult s~!n 
fibroblasts show increased sensitivity to bFGF signaling following 
TGF-p pretreatment, whereas the scleroderma fibroblast shoWS In-
creased sensitivity to PDGF-AA signaling after TGF-fJ pret~eat­
ment. Therefore, using these cells under these in vitro condltwnd the opposing TGF-p effects on subsequent responses to bFGF an 
PDGF may occur via independent pathways, making it difficult ~o 
generalize regarding the role of TGF-fJ in the biology of fibrOSIS. 
One might also predict that the TGF-fJ-induced heightened. mitO-
genicity of healthy adul t skin fibroblasts would not be selective fo~ 
high collagen producing fibroblasts and that the fibroblasts so sumu 
lated by bFGF would not show increased collagen mRNA or pro-
tein levels. Thus, the bFGF mitogenic system might be useful ~~ 
compare and contrast with the PDGF system. These speculauo 
are presently testable. 
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